Imagine a future where stubborn skin conditions like eczema and psoriasis are not just managed, but truly conquered. This is the bold vision driving groundbreaking research in dermatology, and Christopher Bunick, MD, PhD, is at the forefront of this revolution. In a recent interview with Dermatology Times at the South Beach Symposium 2026, Dr. Bunick, associate professor of dermatology at Yale School of Medicine and editor-in-chief of Dermatology Times, unveiled exciting developments that could transform the way we treat inflammatory skin diseases. But here's where it gets controversial: are we aiming high enough with current treatments, or is there a need to redefine what 'success' looks like for patients? And this is the part most people miss: the future of dermatology isn’t just about managing symptoms—it’s about achieving deeper, more lasting relief through precision medicine.
Dr. Bunick shed light on the evolving landscape of therapies, particularly for conditions like atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS). These diseases, he explained, are driven by complex, overlapping inflammatory pathways, making them notoriously difficult to treat with single-target approaches. While existing biologics—primarily targeting TH2 cytokines—have been game-changers, they often fall short of addressing the full spectrum of disease biology. Enter bispecific and trispecific biologics, a new class of treatments designed to tackle multiple pathways simultaneously. These innovative therapies aim not just to clear skin, but to significantly improve itch, pain, and overall quality of life. But will they live up to the hype? Only time—and rigorous clinical trials—will tell.
Beyond biologics, Dr. Bunick highlighted the rise of selective intracellular signaling inhibitors, with a spotlight on tyrosine kinase 2 (TYK2) inhibitors. Here’s where it gets fascinating: while TYK2 is part of the Janus kinase (JAK) family, its inhibitors work differently. Unlike traditional JAK inhibitors, which target the kinase domain, TYK2 inhibitors act on the regulatory or allosteric domain, offering greater selectivity and potentially fewer side effects. But here’s the catch: are we sacrificing efficacy for safety, or can we truly have the best of both worlds? First-generation TYK2 inhibitors like deucravacitinib have already shown promise in psoriasis, with over four years of data supporting their safety and efficacy. Next-generation options, such as zasocitinib and envudeucitinib, are poised to raise the bar even higher, with phase 3 data for zasocitinib expected soon. However, side effects like acneiform eruptions and folliculitis remain a concern, though generally manageable.
What’s particularly compelling is the genetic evidence backing TYK2 as a safe target. Naturally occurring human variants with reduced TYK2 function are associated with lower rates of immune-mediated diseases, suggesting that inhibiting this pathway could be both effective and safe. But this raises a thought-provoking question: if TYK2 inhibition is so promising, why isn’t it already the gold standard in dermatology? Could it be that we’re still in the early stages of understanding its full potential?
Looking ahead, Dr. Bunick expressed optimism about the role of JAK and TYK2 inhibitors in treating conditions with unmet needs, such as vitiligo, alopecia areata, dermatomyositis, and HS. In HS, he called for higher clinical trial benchmarks, challenging the field to move beyond modest response rates and aim for transformative outcomes. “I really want to see the endpoint bar being raised,” he emphasized. But this begs the question: are we setting unrealistic expectations, or is this the push the field needs to innovate?
Collectively, these advancements paint a picture of a dermatology landscape increasingly defined by pathway specificity, improved safety, and higher expectations for durable disease control. But here’s the ultimate question for you: As these therapies continue to evolve, what outcomes matter most to patients? Is it complete clearance, symptom relief, or something else entirely? Share your thoughts in the comments—let’s spark a conversation that could shape the future of dermatology.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
